Our results do differ from some other studies," Zervos told a news conference. "What we think was important in ours ...
is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid," he added.
Much more work needs to be done to elucidate what the final treatment plan should be for Covid-19," Kalkanis added. "But we feel ... that these are critically important results to add to the mix of how we move forward if there's a second surge, and in relevant other parts of the world. Now we can help people combat this disease and to reduce the mortality rate."
Zervos said
hydroxychloroquine can help interfere with the virus directly and also reduces inflammation.
The Henry Ford team wrote that 82% of their patients received hydroxychloroquine within the first 24 hours of admission, and 91% within the first 48 hours of admission.
They wrote that in comparison, a study of patients at 25 New York hospitals started taking the drug "at any time during their hospitalization."
But patients in that New York study, published in May in the Journal of the American Medical Association, started taking hydroxychloroquine on average one day after being hospitalized.
While helpful, observational studies are not as valuable as controlled clinical trials. Considered the gold standard in medicine, patients in a clinical trial are randomly assigned to take either the drug or a placebo, which is a treatment that does nothing. Doctors then follow the patients to see how they fare.
https://www.cnn.com/2020/07/02/healt...udy/index.html
Bookmarks